Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families

  • Juana Fernández-Rodríguez1,
  • Francisco Quiles1,
  • Ignacio Blanco1,
  • Alex Teulé1,
  • Lídia Feliubadaló1,
  • Jesús del Valle1,
  • Mónica Salinas1,
  • Àngel Izquierdo2,
  • Esther Darder2,
  • Detlev Schindler3,
  • Gabriel Capellá1,
  • Joan Brunet2,
  • Conxi Lázaro1Email author and
  • Miguel Angel Pujana4Email author
Contributed equally
BMC Cancer201212:84

DOI: 10.1186/1471-2407-12-84

Received: 13 September 2011

Accepted: 8 March 2012

Published: 8 March 2012

Abstract

Background

Genes that, when mutated, cause Fanconi anemia or greatly increase breast cancer risk encode for proteins that converge on a homology-directed DNA damage repair process. Mutations in the SLX4 gene, which encodes for a scaffold protein involved in the repair of interstrand cross-links, have recently been identified in unclassified Fanconi anemia patients. A mutation analysis of SLX4 in German or Byelorussian familial cases of breast cancer without detected mutations in BRCA1 or BRCA2 has been completed, with globally negative results.

Methods

The genomic region of SLX4, comprising all exons and exon-intron boundaries, was sequenced in 94 Spanish familial breast cancer cases that match a criterion indicating the potential presence of a highly-penetrant germline mutation, following exclusion of BRCA1 or BRCA2 mutations.

Results

This mutational analysis revealed extensive genetic variation of SLX4, with 21 novel single nucleotide variants; however, none could be linked to a clear alteration of the protein function. Nonetheless, genotyping 10 variants (nine novel, all missense amino acid changes) in a set of controls (138 women and 146 men) did not detect seven of them.

Conclusions

Overall, while the results of this study do not identify clearly pathogenic mutations of SLX4 contributing to breast cancer risk, further genetic analysis, combined with functional assays of the identified rare variants, may be warranted to conclusively assess the potential link with the disease.

Background

A functionally coherent network of gene and/or protein interactions, altered in Fanconi anemia (FA) and breast cancer (BrCa), has emerged in recent years [1]. Fifteen genes that, when mutated, cause FA (FANC genes) and several genes that may harbor mutations of high, moderate or low penetrance for BrCa risk encode for proteins that converge on a homology-directed DNA damage repair process [2]. As further evidence of a fundamental common causal basis between these diseases, germline bi- and mono-allelic loss-of-function mutations in four of these genes cause FA and BrCa, respectively: FANCD1/BRCA2 [3, 4], FANCJ/BRIP1 [58], FANCN/PALB2 [911] and FANCO/RAD51C [12, 13] (more recent data suggests that mutations in RAD51C may be primarily linked to ovarian cancer risk [14]). This evidence marks any novel gene involved in the aforementioned network or process as a candidate to harbor mutations in unclassified FA and/or BrCa patients.

Interstrand DNA cross-link agents, such as mitomycin-C used in diagnostic tests for FA, block replication forks and may therefore cause genome instability. Homologs of SLX4 in model organisms were initially identified as necessary for replication fork restart following exposure to DNA-damaging agents [15]. Subsequently, SLX4 homologs have been shown to play a key role as docking molecules for the repair of interstrand cross-links [16, 17]. These observations pointed to the human SLX4 gene as a FANC candidate for unclassified patients and, as a result, two groups have recently described mutations (renamed FANCP gene or FA-P subtype) [18, 19]. The potential link to BrCa risk has been examined, to date, in 52 German or Byelorussian patients with familial breast cancer [20]: the study has not revealed truncating or clearly pathogenic mutations, but has identified four unclassified missense variants. Here, we conducted a more detailed study of the SLX4 gene in 94 index BrCa cases from Spanish families negative for BRCA1 and BRCA2 mutations. As recently reported [20], our results do not show truncating or clearly pathogenic mutations, although they do describe seven missense variants of unknown biological significance that are not found in controls.

Methods

Study samples

Since its creation in 1999, the Hereditary Cancer Program at the ICO has identified a set of high-risk families with suspected hereditary breast and/or ovarian cancer syndrome. Following the Catalan Consensus Onco Guidelines on genetic testing for this condition, patients are analysed for mutations in the BRCA1 or BRCA2 genes after receiving appropriate genetic counselling and providing written informed consent. This genetic analysis consists of screening for point mutations and large rearrangements affecting those genes. For the present study, a total of 94 affected individuals belonging to 94 unrelated families negative for BRCA1 or BRCA2 mutations were selected. In addition to negativity for mutations in BRCA1 or BRCA2, the inclusion criteria were: at least three first-degree relatives affected by breast or ovarian cancer; or at least two first-degree female relatives affected by breast cancer (at least one of them diagnosed before the age of 50); or at least one case of female breast cancer plus at least one case of either ovarian, female bilateral breast, or male breast cancer. Among the selected cases, 10 families were represented with an elevated prior risk of harboring a high-penetrance mutation, as calculated with the BRCAPRO [21] algorithm (briefly, 94 families mean = 0.40, standard deviation = 0.26, 95% confidence interval 0.11-0.99). Control samples, consisting of 138 women and 146 men, were taken from a hospital-based cancer association study (a detailed description of the study population, composition and interviews has been given elsewhere [22]). Specifically, these individuals were randomly enrolled from non-cancer patients admitted to the same general hospital as the BrCa cases. To avoid selection bias, the inclusion criterion for controls was that the current admission to the hospital should be for a new disease (not previously diagnosed). The studies were approved by the IDIBELL ethics committee and participants gave written informed consent for their participation, and for the genetic analysis of their biological samples, according to the Declaration of Helsinki.

Mutation analysis

The SLX4 exons and exon-intron boundaries were sequenced from polymerase chain reactions using previously defined primers and conditions [18]; for exon 7, AmpliTaq Gold DNA Polymerase (Applied Biosystems) and 10% of dimethyl sulfoxide were used. The reaction products were purified from remaining primers using ExoSAP-IT (GE Healthcare) and sequencing reactions performed following a standard Sanger method with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Samples harboring DNA variants were re-sequenced at least once using an independent DNA aliquot from the first-pass analysis. The guidelines of the Human Genome Variation Society and the reference sequences NM_032444.2 and NP_115820.2 of the National Center for Biotechnology Information were used for nomenclature.

Genotyping

Assays based on the KASPar technology were performed following the manufacturer's instructions (KBioscience). Reactions were carried out in a 384-well format with 2% of duplicates, and negative and positive (i.e. BrCa patient carrier) sample controls present in each plate.

Results and discussion

The genomic region of SLX4, comprising all exons and exon-intron boundaries, was sequenced in 94 BrCa familial cases that match a criterion indicating the potential presence of a highly-penetrant germline mutation, following exclusion of BRCA1 or BRCA2 mutations (see Methods). This mutational analysis revealed 49 variants: 21 novel and 28 which are currently annotated in the single nucleotide polymorphism database (dbSNP [23]) (Table 1). Of the 49 variants, 21 were found only once, which include three changes identified by the 1,000 Genomes Project [24] (Table 1): rs72778139-T has no known frequency data; rs76488917-A has an allele frequency of 0.02 in Caucasians; and rs115694169-A has an allele frequency of 0.03 in the Yoruba people of Ibadan (there is no data for Caucasians). Excluding these from the set of 21 with low frequency revealed eight missense and five silent changes at the protein level, and five intronic changes (Table 1). A neural network splicing prediction [25] model did not strongly support alteration by any of the identified intronic variants (data not shown). Together, these results suggest extensive genetic variation at the SLX4 locus among individuals in our population, but provide no obvious link to BrCa risk.
Table 1

SLX4 variants found in non-BRCA1/2-mutated familial BrCa cases

Exon

Nucleotide change

Change

type

Amino acid change

Number of carriers*

dbSNP†

    

Het (%)

Hom (%)

Total

 

2

c.248G > C

Missense

p.Gly83Ala

1 (1.1)

0

94

NA

2

c.339T > C

Silent

p. =

1 (1.1)

0

94

NA

2

c.421G > T

Missense

p.Gly141Trp

1 (1.1)

0

94

NA

3

c.555C > T

Silent

p. =

9 (9.5)

0

94

rs74640850

3

c.610C > T

Missense

p.Arg204Cys

10 (10.6)

0

94

rs79842542

3

c.678C > T

Silent

p. =

3 (3.2)

0

94

rs28516461

3

c.590T > C

Missense

p.Val197Ala

1 (1.1)

0

94

NA

3

c.710G > A

Missense

p.Arg237Gln

2 (2.1)

0

94

NA

3

c.753G > A

Silent

p. =

24 (25.5)

2 (2.1)

94

rs8061528

4

c.761-32T > G

Intronic

p. =

2 (2.1)

0

94

NA

5

c.1152A > G

Silent

p. =

11 (11.7)

0

94

rs112511042

5

c.1153C > A

Missense

p.Pro385Thr

1 (1.1)

0

94

rs115694169

5

c.1156A > G

Missense

p.Met386Val

11 (11.7)

0

94

rs113490934

5

c.1163 + 10C > T

Intronic

p. =

11 (11.7)

0

94

rs80116508

6

c.1164-16T > C

Intronic

p. =

1 (1.1)

0

94

NA

6

c.1164-40C > A

Intronic

p. =

1 (1.1)

0

94

NA

6

c.1164-66T > A

Intronic

p. =

2 (2.1)

0

94

NA

6

c.1164-75C > G

Intronic

p. =

11 (11.7)

0

94

rs59622164

6

c.1366 + 11T > C

Intronic

p. =

12 (12.8)

0

94

rs76350200

7

c.1371T > G

Missense

p.Asn457Lys

10 (10.6)

0

94

rs74319927

7

c.1419C > T

Silent

p. =

1 (1.1)

0

94

NA

8

c.1846G > A

Missense

p.Val616Met

1 (1.1)

0

94

NA

9

c.2012T > C

Missense

p.Leu671Ser

11 (11.8)

0

93

rs77985244

9

c.2013 + 23G > A

Intronic

p. =

11 (11.7)

0

94

rs112226642

9

c.2013 + 137G > C

Intronic

p. =

11 (11.7)

0

94

rs80186343

10

c.2160 + 50C > T

Intronic

p. =

10 (10.6)

0

94

rs75762935

12

c.2346C > T

Silent

p. =

1 (1.1)

0

94

NA

12

c.2469G > C

Missense

p.Trp823Cys

1 (1.1)

0

94

NA

12

c.2854G > A

Missense

p.Ala952Thr

8 (8.5)

0

94

rs59939128

12

c.2855C > T

Missense

p.Ala952Val

8 (8.5)

0

94

rs78637028

12

c.3162G > A

Silent

p. =

1 (1.1)

0

94

rs76488917

12

c.3365C > T

Missense

p.Pro1122Leu

12 (12.8)

1 (1.1)

94

rs714181

12

c.3662C > T

Missense

p.Ala1221Val

10 (10.6)

0

94

rs3827530

12

c.3812C > T

Missense

p.Ser1271Phe

4 (4.2)

0

94

rs3810813

12

c.3872C > T

Missense

p.Thr1291Met

1 (1.1)

0

94

NA

12

c.4261A > T

Missense

p.Ile1421Phe

1 (1.1)

0

94

NA

12

c.4409C > T

Missense

p.Pro1470Leu

1 (1.1)

0

94

rs72778139

12

c.4500T > C

Silent

p. =

42 (44.7)

21 (22.3)

94

rs3810812

12

c.4530G > T

Silent

p. =

1 (1.1)

0

94

NA

13

c.4637-125C > T

Intronic

p. =

1 (1.1)

0

94

NA

13

c.4637-227C > T

Intronic

p. =

9 (9.6)

0

94

rs75693937

13

c.4739 + 10C > T

Intronic

p. =

1 (1.1)

0

94

NA

13

c.4739 + 24G > T

Intronic

p. =

20 (21.3)

2 (2.1)

94

rs12933120

14

c.5072A > G

Missense

p.Asn1691Ser

1 (1.1)

0

94

NA

15

c.5389C > T

Silent

p. =

1 (1.1)

0

93

NA

15

c.5501A > G

Missense

p.Asn1834Ser

2 (2.2)

0

93

rs111738042

15

c.*8A > G

Intronic

p. =

9 (9.7)

0

93

rs3751839

15

c.*102G > A

Intronic

p. =

1 (1.1)

0

93

NA

15

c.*113C > T

Intronic

p. =

8 (8.6)

0

93

rs76661336

*Het, heterozygous; Hom, homozygous

†Build 133; NA, not applicable

Having identified rare variants in BrCa familial cases, we next assessed the presence of 10 of these variants in a cohort of controls collected at the same hospital as the cases (see Methods). The selection of these variants was based on the observed low frequency in the 94 BrCa cases and on their identification as missense variations. In addition, a causative prediction was obtained using two algorithms (PolyPhen-2 [26] and SIFT [27]), plus a weighted average of scores (Condel [28]). Seven of these variants were not found in controls and, intriguingly, five of them were predicted to be "deleterious" (Table 2). Among this group, only one amino acid position (Trp823) showed some evolutionary conservation (Figure 1), and the substitution may be disfavored (Trp to Cys) [29]; tumor samples were not available for any case that would have allowed assessment of the existence of loss of heterozygosity at the SLX4 locus. Nonetheless, predictions of a deleterious effect should be taken with caution as neutral polymorphisms can frequently be misclassified (from ~15-50% depending on the method [28]). On the other hand, extensive genetic variation in SLX4 might reflect an unknown evolutionary pressure or could be related to a similar observation made for other DNA repair-related genes [30].
Table 2

Pathological prediction and frequency in controls of selected SLX4 missense variants

Exon

Nucleotide

change

Amino acid

change

dbSNP†

Pathological prediction

Controls

tested (n)

Number of control

carriers (%)

    

SIFT

(score < 0.05, deleterious)

PolyPhen-2

(false positive rate)

Condel

(weighted average

of scores)

Condel

prediction

  

2

c.248G > C

p.Gly83Ala

NA

0.14

0.15

0.15

Neutral

283

0

2

c.421G > T

p.Gly141Trp

NA

0.00

0.86

0.86

Deleterious

284

2 (0.7)

3

c.590T > C

p.Val197Ala

NA

0.48

0.01

0.00

Neutral

284

1 (0.4)

3

c.710G > A

p.Arg237Gln

NA

0.49

0.00

0.38

Neutral

284

4 (1.4)

8

c.1846G > A

p.Val616Met

NA

0.17

0.62

0.80

Deleterious

281

0

12

c.2469G > C

p.Trp823Cys

NA

0.01

1.00

0.97

Deleterious

282

0

12

c.3872C > T

p.Thr1291Met

NA

0.05

0.98

0.99

Deleterious

283

0

12

c.4261A > T

p.Ille1421Phe

NA

0.08

0.77

0.77

Deleterious

285

0

12

c.4409C > T

p.Pro1470Leu

rs72778139

0.02

0.99

0.96

Deleterious

283

0

14

c.5072A > G

p.Asn1691Ser

NA

0.56

0.00

0.01

Neutral

285

0

†Build 133; NA, not applicable

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-12-84/MediaObjects/12885_2011_Article_3089_Fig1_HTML.jpg
Figure 1

CLUSTALW-based multi-alignment of human SLX4 and eukaryotic homologs. The region surrounding human Trp823 is shown.

While SLX4 serves as a scaffold for multiple proteins involved in the DNA damage response [16, 17], the functional involvement of the Trp823 position, and of the other rare variants not found in controls in this study, is unknown. None of the identified variants changes a critical amino acid residue and there is no data that could suggest an alteration of protein interactions or complexes; however, the Pro1470Leu variant might disrupt a mitotic phosphorylation site at Ser1469 [31, 32]. In this context, a SLX4 pathological variant linked to BrCa should consist of a hypomorphic mutation that would cause genome instability. Accordingly, SLX4 is a key regulator of the function of structure-specific endonucleases involved in the repair of DNA damage; in particular, proper function of SLX4 is fundamental for repair during replication and for resolving Holliday junctions formed during homologous recombination [16, 17, 33, 34]. Overall, the results of this study do not support the existence of loss-of-function mutations of SLX4 associated with BrCa risk; nonetheless, further genetic analysis in patients and controls, combined with functional assays of specific rare variants, may be warranted.

Conclusions

The mutational analysis of SLX4 in 94 familial BrCa index cases without mutations in BRCA1 or BRCA2 has revealed extensive genetic variation. Twenty-nine novel single nucleotide variants have been detected, 21 of them showing relatively low allele frequencies: however, none can be linked to a clear alteration of the protein function. Nonetheless, analysis of 10 of these variants failed to detect seven of them in a set of controls. While the results of this study do not support the common existence of SLX4 mutations contributing to BrCa risk, additional studies may be warranted.

Notes

Abbreviations

BrCa: 

Breast cancer

BRCAPRO: 

BRCA carrier prediction model

Condel: 

Consensus deleteriousness score

dbSNP: 

Single nucleotide polymorphism database

DNA: 

Deoxyribonucleic acid

FA: 

Fanconi anemia

Het: 

Heterozygous

Hom: 

Homozygous

PolyPhen: 

Polymorphism phenotyping

SIFT: 

Sorting intolerant from tolerant

SLX4 Structure-specific endonuclease subunit homolog

(S. cerevisiae) gene.

Declarations

Acknowledgements

We wish to thank all study participants, clinicians, centers and members of the case-control study at the Catalan Institute of Oncology for their valuable contributions. The authors recognize the following grants provided to support this study: Generalitat de Catalunya 2009SGR290 to IB and CL, and 2009-SGR283 to MAP; Spanish Association Against Cancer (AECC groups) to GC; Spanish Ministry of Health "Instituto de Salud Carlos III" 10/31488, 10/01422, and 09/02483 to IB, CL, and MAP, respectively; 2009 Spanish Society of Medical Oncology to JB; and CIBERESP group 55 and Ramón Areces Foundation XV to MAP. JF-R was supported by a research support contract (CA08/00248) from the "Instituto de Salud Carlos III".

Authors’ Affiliations

(1)
Hereditary Cancer Program, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet
(2)
Hereditary Cancer Program, ICO, Hospital Josep Trueta, Girona Biomedical Research Institute (IdIBGi)
(3)
Department of Human Genetics, University of Würzburg
(4)
Translational Research Laboratory, Biomedical Research Center Network for Epidemiology and Public Health (CIBERESP), ICO, IDIBELL, L'Hospitalet

References

  1. Wang W: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007, 8: 735-748.View ArticlePubMedGoogle Scholar
  2. D'Andrea AD: Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010, 362: 1909-1919. 10.1056/NEJMra0809889.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002, 297: 606-609. 10.1126/science.1073834.View ArticlePubMedGoogle Scholar
  4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.View ArticlePubMedGoogle Scholar
  5. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006, 38: 1239-1241. 10.1038/ng1902.View ArticlePubMedGoogle Scholar
  6. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, et al: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005, 37: 931-933. 10.1038/ng1624.View ArticlePubMedGoogle Scholar
  7. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, et al: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005, 37: 934-935. 10.1038/ng1625.View ArticlePubMedGoogle Scholar
  8. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB: BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005, 8: 255-265. 10.1016/j.ccr.2005.08.004.View ArticlePubMedGoogle Scholar
  9. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, et al: A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007, 446: 316-319. 10.1038/nature05609.View ArticlePubMedGoogle Scholar
  10. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, et al: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007, 39: 162-164. 10.1038/ng1947.View ArticlePubMedGoogle Scholar
  11. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39: 165-167. 10.1038/ng1959.View ArticlePubMedGoogle Scholar
  12. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010, 42: 410-414. 10.1038/ng.569.View ArticlePubMedGoogle Scholar
  13. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, et al: Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010, 42: 406-409. 10.1038/ng.570.View ArticlePubMedGoogle Scholar
  14. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H: RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011, 20: 3278-3288. 10.1093/hmg/ddr229.View ArticlePubMedGoogle Scholar
  15. Roberts TM, Kobor MS, Bastin-Shanower SA, Ii M, Horte SA, Gin JW, Emili A, Rine J, Brill SJ, Brown GW: Slx4 regulates DNA damage checkpoint-dependent phosphorylation of the BRCT domain protein Rtt107/Esc4. Mol Biol Cell. 2006, 17: 539-548.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, Harper JW: Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell. 2009, 138: 63-77. 10.1016/j.cell.2009.06.030.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Fekairi S, Scaglione S, Chahwan C, Taylor ER, Tissier A, Coulon S, Dong MQ, Ruse C, Yates JR, Russell P, et al: Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell. 2009, 138: 78-89. 10.1016/j.cell.2009.06.029.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, Oostra AB, Eirich K, Korthof ET, Nieuwint AW, et al: SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011, 43: 138-141. 10.1038/ng.751.View ArticlePubMedGoogle Scholar
  19. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A: Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011, 43: 142-146. 10.1038/ng.750.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Landwehr R, Bogdanova NV, Antonenkova N, Meyer A, Bremer M, Park-Simon TW, Hillemanns P, Karstens JH, Schindler D, Dork T: Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. Breast Cancer Res Treat. 2011, 130: 1021-1028. 10.1007/s10549-011-1681-1.View ArticlePubMedGoogle Scholar
  21. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, et al: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002, 94: 844-851. 10.1093/jnci/94.11.844.View ArticlePubMedGoogle Scholar
  22. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F: Association of common polymorphisms in inflammatory genes interleukin (IL) 6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003, 63: 3560-3566.PubMedGoogle Scholar
  23. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29: 308-311. 10.1093/nar/29.1.308.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Consortium GP: A map of human genome variation from population-scale sequencing. Nature. 2010, 467: 1061-1073. 10.1038/nature09534.View ArticleGoogle Scholar
  25. Reese MG, Eeckman FH, Kulp D, Haussler D: Improved splice site detection in Genie. J Comput Biol. 1997, 4: 311-323. 10.1089/cmb.1997.4.311.View ArticlePubMedGoogle Scholar
  26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods. 2010, 7: 248-249. 10.1038/nmeth0410-248.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009, 4: 1073-1081. 10.1038/nprot.2009.86.View ArticlePubMedGoogle Scholar
  28. González-Pérez A, Lopez-Bigas N: Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011, 88: 440-449. 10.1016/j.ajhg.2011.03.004.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Betts MJ, Russell RB: Amino acid properties and consequences of subsitutions. Bioinformatics for Geneticists. Edited by: Barnes MR, Gray IC. 2003, Chichester: John Wiley and Sons, 289-316.View ArticleGoogle Scholar
  30. Mohrenweiser HW, Wilson DM, Jones IM: Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res. 2003, 526: 93-125. 10.1016/S0027-5107(03)00049-6.View ArticlePubMedGoogle Scholar
  31. Cantin GT, Yi W, Lu B, Park SK, Xu T, Lee JD, Yates JR: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res. 2008, 7: 1346-1351. 10.1021/pr0705441.View ArticlePubMedGoogle Scholar
  32. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA. 2008, 105: 10762-10767. 10.1073/pnas.0805139105.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Crossan GP, van der Weyden L, Rosado IV, Langevin F, Gaillard PH, McIntyre RE, Gallagher F, Kettunen MI, Lewis DY, Brindle K, et al: Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet. 2011, 43: 147-152. 10.1038/ng.752.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Wechsler T, Newman S, West SC: Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature. 2011, 471: 642-646. 10.1038/nature09790.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/84/prepub

Copyright

© Fernández-Rodríguez et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement